BioPharma

Roche has announced it will invest US$50 billion in the US over the next few years in a move that appears aimed at mitigating the risk of tariffs.

Pfizer has launched Part of the Story to mark World Book Day today, advocating a global campaign to help reimagine traditional cancer narratives and keep pace with science.

The release of the Trump administration's terms of reference for its trade negotiations with India has revealed no significant interest in pharmaceutical issues, despite the country's standing as one of the worst offenders on intellectual property protection.

Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.

Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.

Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

Race Oncology (ASX:RAC) has announced the activation of the second site for patient enrolment for its Phase 1 clinical trial of RC220 (bisantrene), combined with doxorubicin, in patients with advanced solid tumours.

Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.

Another positive development for Lilly's weight-loss portfolio, with the company reporting positive results from its Phase 3 trial of a once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist.

New Zealand's Pharmac is proposing to increase the dispensed quantities for a type of asthma inhaler to provide for a three-month supply.

Australia's regulator looks increasingly isolated after the European Union approved Eisai and Biogen's monoclonal antibody LEQEMBI (lecanemab) for early Alzheimer's Disease.

Patients and carers will replace industry employees on FDA advisory committees following a decision by Commissioner Dr Martin Makary that is less practically replicable in Australia.